poisar

Stock

Fulcrum Therapeutics, Inc. FULC

$3.73+0.54%

Overview

FULC market data

Price History

FULC price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.18
Diluted earnings per share over the trailing twelve months.
Beta
2.63
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
8.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.83 – $15.74
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $288M · P/B 2.14 · P/S 3.53.

Company News

10 captured
8-K filing — Fulcrum Therapeutics, Inc. (FULC)SEC EDGAR · Aug 10, 2026, 12:43 PM
UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring ChargesBenzinga · Jun 4, 2026, 8:20 PM
What's Going On With Fulcrum Therapeutics Stock On Thursday?Benzinga · Jun 4, 2026, 2:25 PM
JP Morgan Downgrades Fulcrum Therapeutics to UnderweightBenzinga · Jun 3, 2026, 3:35 PM
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3Benzinga · Jun 2, 2026, 5:57 PM
Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3Benzinga · Jun 2, 2026, 5:23 PM
Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4Benzinga · Jun 2, 2026, 4:15 PM
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4Benzinga · Jun 2, 2026, 1:23 PM
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jun 2, 2026, 1:15 PM
This Goldman Sachs Analyst Turns Bearish; Here Are Top 4 Downgrades For TuesdayBenzinga · Jun 2, 2026, 12:59 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock